Shuttle Pharmaceuticals
SHPH
5 hedge funds and large institutions have $338K invested in Shuttle Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 6 closing their positions.
215% more capital invested
Capital invested by funds: $107K → $338K (+$231K)
15.37% more ownership
Funds ownership: 0.99% → 16.36% (+15%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
38% less funds holding
Funds holding: 8 → 5 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$514K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$159K |
| 3 |
Barclays
London,
United Kingdom
|
+$4.91K |
| 4 |
KFA
Kelleher Financial Advisors
New York
|
+$393 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$46.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$31.4K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$13.8K |
| 4 |
VF
Virtu Financial
New York
|
-$8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.85K |
SHPH Hedge Fund Activity: Q2 2026 in Review
5 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q2 2026, worth a combined $338K — up 215% from $107K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SHPH and 3 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $514K. The largest seller was Ikarian Capital, exiting entirely with an estimated $46.8K sold.
- 5 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q2 2026, down from 8 in Q1 2026.
- Funds reported $338K of Shuttle Pharmaceuticals stock for Q2 2026, up 215% quarter-over-quarter.
- 3 funds opened new Shuttle Pharmaceuticals positions in Q2 2026 and 6 closed out, a net change of -3 holders.
- The largest Shuttle Pharmaceuticals buyer in Q2 2026 was HRT Financial, an estimated $514K added.
- The largest Shuttle Pharmaceuticals seller in Q2 2026 was Ikarian Capital, an estimated $46.8K sold.
Based on aggregated 13F filings for Q2 2026.